Morgan Stanley raises PT on Halozyme Therapics (Halo), after Q2 results

Halozyme Therapics, Inc. (Nasdaq:HaloHe is one of The best growth shares in the middle of the maximum purchase, according to hedge boxes. On August 5, Halozyme Therapeutics, Inc. released. (Nasdaq: Halo) The results of the second quarter of the second quarter of 2025 and raised its financial guidelines for this year. The Wall Street analysts have been optimistic about the shares, and the share price has risen by more than 20 % since the announcement.

Recently, on August 17, Morgan Steanley Sean Laan, the target of the targeted company, raised the target of Halozymemethutics, Inc. (Nasdaq: Halo) from $ 75 to $ 80, while maintaining a purchase on the arrow. He pointed out that the company raised revenues and EPS directions, and then the revenue is expected to be 11 % higher than the initial guidance, while the arrow’s profitability is expected to be 20 % higher. The administration has raised predictions due to strong sales sales and good cost control.

Although the company has not yet revealed its long -term view from 2026 to 2028, the analyst believes that expectations will improve, driven by major products.

Halozyme Therapics, Inc. (Nasdaq: Halo) by developing medicine delivery technology to improve how to give medicines to patients. Their main product is Endanze, which helps medications to inject them under the skin more quickly and easily.

While we acknowledge the capabilities of Halo as an investment, we believe that some artificial intelligence shares provide greater potential and carry less risks on the negative side. If you are looking for a stock of artificial intelligence with less than very apprecia The best inventory of artificial intelligence in the short term.

Read the following: 30 stocks must double in 3 years and 11 stocks of hidden artificial intelligence for purchase now.

Detection: Nothing. This article was originally published in A monkey from the inside.